# Nephros Inc: Form 10-Q for the period ended Sep 30, 2019

- Company: [Nephros Inc](/companies/neph.md) (CIK 1196298)
- Form: 10-Q
- Filed: 2019-11-06
- Accepted by EDGAR: Nov 6, 2019, 07:31 ET
- Period: 2019-09-30
- Accession: 0001493152-19-016513
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1196298/000149315219016513/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1196298/000149315219016513/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $3.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $7.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $1.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $3.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $1.8m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | $4.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-07-01 to 2019-09-30 | $777.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2019-01-01 to 2019-09-30 | $2.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2019-07-01 to 2019-09-30 | $1.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2019-01-01 to 2019-09-30 | $4.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | −$695.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-07-01 to 2019-09-30 | $48.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2019-01-01 to 2019-09-30 | $140.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | −$804.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | −$3.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | −$0.10 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-30 | −$0.43 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | −$2.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-01-01 to 2019-09-30 | $14.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-09-30 | $3.9m | us-gaap:Cash |
| Current assets | at 2019-09-30 | $8.1m | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $11.6m | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $3.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $4.8m | us-gaap:Liabilities |
| Long-term debt | at 2019-09-30 | $879.0k | us-gaap:LongTermDebt |
| Shareholders' equity | at 2019-09-30 | $3.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 51,037 characters.

*This discussion should be read in conjunction with our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q and the notes thereto, as well as the other sections of this Quarterly Report on Form 10-Q, including the “Forward-Looking Statements” section hereof, and our Annual Report on Form 10-K for the year ended December 31, 2018, including the “Risk Factors” and “Business” sections thereof. This discussion contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risk factors described in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2018. Our actual results may differ materially.*

### Business Overview

We are a commercial-stage company that develops and sells high performance water purification products to the medical device and commercial markets.

In medical device markets, our filters, generally classified as ultrafilters, are used primarily by hospitals for the prevention of infection from water-borne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. Because our ultrafilters capture contaminants as small as 0.005 microns in size, they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins.

In commercial markets, we manufacture and sell filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Marketed under both the Nephros and AETHER™ brands, our products are used in the health care, food service, hospitality, and convenience store markets.

Our subsidiary, Specialty Renal Products, Inc. (“SRP”), is a development-stage medical device company, focused primarily on developing hemodiafiltration (“HDF”) technology. SRP is developing a second generation of the OLpūr H2H Hemodiafiltration System, the only U.S. Food and Drug Administration (“FDA”) 510(k)-cleared medical device that enables nephrologists to provide HDF treatment to patients with end stage renal disease (“ESRD”).

On December 31, 2018, we entered into a Membership Interest Purchase Agreement (the “Agreement”) with Biocon1, LLC, a Nevada limited liability company (“Biocon”), Aether Water Systems, LLC, a Nevada limited liability company (“Aether”), and Gregory Lucas, the sole member of each of Biocon and Aether. Pursuant to the terms of the Agreement, we acquired 100% of the outstanding membership interests of each of Biocon and Aether (the “Biocon Acquisition”).

We were founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize an alternative method to hemodialysis. We have extended our filtration technologies to meet the demand for liquid purification in other areas, in particular water purification.

### Reverse Stock Split

On July 9, 2019, we effected a reverse stock split, in which every nine shares of our common stock issued and outstanding immediately prior to the effective time, which was 5:30 p.m. ET on July 9, 2019, were combined into one share of common stock. Fractional shares were not issued and stockholders who otherwise would have been entitled to receive a fractional share as a result of the reverse stock split received an amount in cash equal to $5.58 per share for such fractional interests. The number of shares of our common stock issued and outstanding was reduced from approximately 69,000,000 to approximately 7,700,000.

All of the share and per share amounts discussed in this Quarterly Report on Form 10-Q have been adjusted to reflect the effect of this reverse split.

### Our Products

### Water Filtration Products

We develop and sell liquid filtration products used in both medical and commercial applications, employing multiple filtration technologies.

In medical markets, our primary filtration mechanism is to pass liquids through the pores of polysulfone hollow fiber. Our filters’ pores are significantly smaller than those of competing products, resulting in highly effective elimination of water-borne pathogens, including legionella bacteria (the cause of Legionnaires disease) and viruses, which are not eliminated by most other microbiological filters on the market. Additionally, the fiber structure and pore density in our hollow fiber enables significantly higher flow rates than in other polysulfone hollow fiber.

In commercial markets, with our recent addition of the AETHER product line, carbon-based absorption is the primary filtration mechanism. AETHER products allow us to improve water’s odor and taste, to reduce scale and heavy metals, and to reduce other water contaminants for customers who are primarily in the food service, convenience store, and hospitality industries.

The Biocon business acquisition has the potential to generate accretive revenue growth in at least three potential ways. First, we expect the business to continue its rapid organic growth, which it was experiencing before being acquired. Second, cross-selling opportunities are generated by offering taste/odor-focused products to the medical device markets, as well as pathogen-focused filtration to the commercial markets. Finally, as part of the more substantial Nephros organization, AETHER may be able to compete for larger filtration contracts than may have been available to it as a smaller, independent firm. With nine months of results to date, we have seen some promising results in each of these strategies, but it is still too early to judge the likelihood or magnitude of their long-term success.

Our sales strategy is a combination of direct selling to end customers and indirect selling through value-added resellers (“VARs”). Leveraging VARs has enabled us to expand rapidly our access to target customers in the medical market without significant sales staff expansion. In addition, while we are currently focused in medical markets, the VARs that support these customers also support a wide variety of commercial and industrial customers. We believe that our VAR relationships will facilitate growth in filter sales outside of the medical industry.

#### Target Markets

Our ultrafiltration products currently target the following markets:

- Hospitals and Other Healthcare Facilities: Filtration of water for washing and drinking as an aid in infection control. The filters produce water that is suitable for wound cleansing, cleaning of equipment used in medical procedures, and washing of surgeons’ hands. In addition, we are developing a broad-spectrum diagnostic tool for our hospital and other health care customers to provide them with the ability to assess water safety risks on a real-time basis.
- Dialysis Centers: Filtration of water or bicarbonate concentrate used in hemodialysis.
- Commercial Facilities: Filtration and purification of water for consumption, including for use in ice machines and soft drink dispensers.
- Military and Outdoor Recreation: Individual water purification devices used by soldiers and backpackers to produce drinking water in the field, as well as filters customized to remote water processing systems.

*Hospitals and Other Healthcare Facilities.* According to the American Hospital Association, approximately 6,200 hospitals, with approximately 931,000 beds, treated over 36 million patients in the United States in 2017. The U.S. Centers for Disease Control and Prevention estimates that healthcare associated infections (“HAI”) occurred in approximately 1 out of every 31 hospital patients, or about 687,000 patients in 2015. HAIs affect patients in hospitals or other healthcare facilities and are not present or incubating at the time of admission. They also include infections acquired by patients in the hospital or facility, but appearing after discharge, and occupational infections among staff. Many HAIs are caused by waterborne bacteria and viruses that can thrive in aging or complex plumbing systems often found in healthcare facilities.

The Affordable Care Act, passed in March 2010, puts in place comprehensive health insurance reforms that aim to lower costs and enhance quality of care. With its implementation, healthcare providers have substantial incentives to deliver better care or be forced to absorb the expenses associated with repeat medical procedures or complications like HAIs. As a consequence, hospitals and other healthcare facilities are proactively implementing strategies to reduce HAI potential. Our ultrafilters are designed to aid in infection control in the hospital and healthcare setting by treating facility water at the points of delivery, such as ice machines, sinks and showers.

In June 2017, the Center for Clinical Standards and Quality at the Centers for Medicare and Medicaid Services (“CMS”) announced the addition of requirements for facilities to develop policies and procedures that inhibit the growth and spread of legionella and other opportunistic pathogens in building water systems. Going forward, CMS surveyors will review policies, procedures, and reports documenting water management implementation results to verify that facilities are compliant with these requirements. We believe that these CMS regulations may have a positive impact on the sale of our HAI-inhibiting ultrafilters.

We currently have FDA 510(k) clearance on the following portfolio of medical device products for use in the hospital setting to aid in infection control:

- The DSU-H is an in-line, 0.005-micron ultrafilter that provides dual-stage protection from water borne pathogens. The DSU-H is primarily used to filter potable water feeding ice machines, sinks, and medical equipment, such as endoscope washers and surgical room humidifiers. The DSU-H has an up to 6-month product life when used in a hospital setting.
- The SSU-H is an in-line, 0.005-micron ultrafilter that provides single-stage protection from water borne pathogens. The SSU-H is primarily used to filter potable water feeding sinks, showers and medical equipment. The SSU-H has an up to 3-month product life when used in a hospital setting.
- The S100 is a point-of-use, 0.01-micron microfilter that provides protection from water borne pathogens. The S100 is primarily used to filter potable water feeding sinks and showers. The S100 has an up to 3-month product life when used in a hospital setting.
- The HydraGuardTM and HydraGuardTM - Flush are 0.005-micron cartridge ultrafilters that provide single-stage protection from water borne pathogens. The HydraGuard ultrafilters are primarily used to filter potable water feeding ice machines and medical equipment, such as endoscope washers and surgical room humidifiers. The HydraGuard TM has an up-to 6-month product life and the HydraGuard - Flush has an up to 12-month product life when used in a hospital setting.

We received FDA 510(k) clearance to market the HydraGuard in December 2016 and began shipping it in July 2017. We began shipping the HydraGuard - Flush in September 2017. The DSU-H, SSU-H, and S100 products received FDA 510(k) clearance in prior years.

Our complete hospital infection control product line, including in-line, point-of-use, and cartridge filters, can be viewed on our website at http://www.nephros.com/infection-control/. We are not including the information on our website as a part of, nor incorporating it by reference into, this Quarterly Report on Form 10-Q.

In addition, we are currently developing a water pathogen detection system designed to enable real-time analysis of water for the presence of borne pathogens, which we expect will complement our medical water filtration products. We plan to offer the system initially to customers and prospective customers that focus on infection control, including hospitals, dialysis centers, and other health care facilities. Following the initial launch, we plan to market the system to other markets as well, including those addressed by our AETHER product lines.

Based on discussions with potential partners and customers, we expect the water pathogen detection system to lead to significantly increased sales, as well as to position ourselves and our strategic distribution partners as strategic partners to our customers in the infection control market, providing pathogen detection expertise as well as filtration products. We expect to launch this system initially as a service in late 2019 and to work with our current strategic distribution partners to roll out the system in 2020.

*Dialysis Centers - Water/Bicarbonate.* To perform hemodialysis, all dialysis clinics have dedicated water purification systems to produce water and bicarbonate concentrate, two essential ingredients for making dialysate, the liquid that removes waste material from the blood. According to the American Journal of Kidney Diseases, there are approximately 6,500 dialysis clinics in the United States servicing approximately 468,000 patients annually. We estimate that there are over 100,000 hemodialysis machines in operation in the United States.

Medicare is the main payer for dialysis treatment in the United States. To be eligible for Medicare reimbursement, dialysis centers must meet the minimum standards for water and bicarbonate concentrate quality set by the Association for the Advancement of Medical Instrumentation (“AAMI”), the American National Standards Institute (“ANSI”) and the International Standards Organization (“ISO”). We anticipate that the stricter standards approved by these organizations in 2009 will be adopted by Medicare in the near future.

We currently have FDA 510(k) clearance on the following portfolio of medical device products for use in the dialysis setting to aid in bacteria, virus, and endotoxin retention:

- The DSU-D, SSU-D and SSUmini are in-line, 0.005-micron ultrafilters that provide protection from bacteria, viruses, and endotoxins. All of these products have an up to 12-month product life in the dialysis setting and are used to filter water following treatment with a reverse osmosis (“RO”) system, and to filter bicarbonate concentrate. These ultrafilters are primarily used in the water lines and bicarbonate concentrate lines leading into dialysis machines, and as a polish filter for portable RO machines.
- The EndoPur is a 0.005-micron cartridge ultrafilter that provides single-stage protection from bacteria, viruses, and endotoxins. The EndoPur has an up to 12-month product life in the dialysis setting, and is used to filter water following treatment with an RO system. More specifically, the EndoPur is used primarily to filter water in large RO systems designed to provide ultrapure water to an entire dialysis clinic. The EndoPur is available in 10”, 20”, and 30” configurations.

The EndoPur is a cartridge-based, “plug and play” market entry that requires no plumbing at installation or replacement. In March 2017, we received FDA 510(k) clearance to market the EndoPur filter. We began shipping the EndoPur 10” filter in July 2017 and the 20” and 30” versions in September 2017.

*Commercial and Industrial Facilities.* Our commercial NanoGuard® product line accomplishes ultrafiltration via small pore size (0.005 micron) technology, filtering bacteria and viruses from water. Our recent acquisition of Biocon and Aether - marketed under the AETHER brand - expands our product line to include additional water filtration and purification technologies, primarily focused on improving odor and taste and on reducing scale and heavy metals from filtered water.

We currently market the following portfolio of proprietary products for use in the commercial, industrial, and food service settings:

- The NanoGuard set of products are in-line, 0.005-micron ultrafilter that provides dual-stage retention of any organic or inorganic particle larger than 15,000 Daltons. NanoGuard products are designed to fit a variety of existing plumbing configurations, including 10” and 20” standard housings, and AETHER and Everpure® manifolds. Included in the NanoGuard product line are both conventional and flushable filters.
- The AETHER line of commercial filters, which are also sold with under the Nephros brand, provide a variety of technology solutions that improve water quality in food service, convenience store, hospitality, and industrial applications. AETHER filters improve water taste and odor, and reduce sediment, dirt, rust particles and other solids, chlorine and heavy minerals, lime scale build-up, and both particulate lead and soluble lead.

AETHER products combine effectively with NanoGuard ultrafiltration technologies to offer full-featured solutions to the commercial water market, including to existing users of Everpure filter manifolds.

*Military and Outdoor Recreation.* We developed our individual water treatment device (“IWTD”) in both in-line and point-of-use configurations. Our IWTD allows a soldier in the field to derive drinking water from any freshwater source. This enables the soldier to remain hydrated, to help maintain mission effectiveness and unit readiness, and to extend mission reach. Our IWTD has been validated by the military to meet the NSF Protocol P248 standard. It has also been approved by the U.S. Army Public Health Command and the U.S. Army Test and Evaluation Command for deployment.

In May 2015, we entered into a Sublicense Agreement (the “Sublicense Agreement”) with CamelBak Products, LLC (“CamelBak”). Under this Sublicense Agreement, we granted CamelBak an exclusive, non-transferable, worldwide (with the exception of Italy) sublicense and license, in each case solely to market, sell, distribute, import and export the IWTD. In exchange for the rights granted to CamelBak, CamelBak agreed, through December 31, 2022, to pay us a percentage of the gross profit on any sales made to a branch of the U.S. military, subject to certain exceptions, and to pay us a fixed per-unit fee for any other sales made. CamelBak was also required to meet or exceed certain minimum annual fees payable to us, and, if such fees are not met or exceeded, we may convert the exclusive sublicense to a non-exclusive sublicense with respect to non-U.S. military sales. In the first quarter of 2019, the Sublicense Agreement was amended to eliminate the minimum fee obligations starting May 6, 2018 and, as such, Camelbak has no further minimum fee obligations. CamelBak product sales have been slower than originally hoped. However, military contracts often take years to close, and we remain optimistic about these products and markets.

### Specialty Renal Products: HDF System

#### Introduction to HDF

The current standard of care in the United States for patients with chronic renal failure is hemodialysis (“HD”), a process in which toxins are cleared via diffusion. Patients typically receive HD treatments at least 3 times weekly for 3-4 hours per treatment. HD is most effective in removing smaller, easily diffusible toxins. For patients with acute renal failure, the current standard of care in the United States is hemofiltration (“HF”), a process where toxins are cleared via convection. HF offers a much better removal of larger sized toxins when compared to HD; however, HF treatment is more challenging for patients, as it is performed on a daily basis, and typically takes 12-24 hours per treatment.

Hemodiafiltration (“HDF”) is an alternative dialysis modality that combines the benefits of HD and HF into a single therapy by clearing toxins using both diffusion and convection. Though not widely used in the United States, HDF is prevalent in Europe and is performed for a growing number of patients. Clinical experience and literature show the following clinical and patient benefits of HDF:

- Enhanced clearance of middle and large molecular weight toxins
- Improved survival - up to a 35% reduction in mortality risk
- Reduction in the occurrence of dialysis-related amyloidosis
- Reduction in inflammation
- Reduction in medication such as EPO and phosphate binders
- Improved patient quality of life
- Reduction in number of hospitalizations and overall length of stay

28

However, like HD, HDF can be resource-intensive and can require a significant amount of time to deliver one course of treatment.

#### Nephros HDF Background

Over the course of our history, we originally developed a medical device that enabled a standard HD machine to perform HDF. We refer to our approach as an on-line mid-dilution hemodiafiltration (“mid-dilution HDF”) system. Our original solution included an OLpūr H2H Hemodiafiltration Module (“H2H Module”), an OLpūr MD 220 Hemodiafilter (“HDF Filter”) and an H2H Substitution Filter (“Dialysate Filter”).

Our H2H Module attaches to a standard HD machine to perform on-line HDF therapy. The HD machine controls and monitors the basic treatment functions, as it would normally when providing HD therapy. The H2H Module is a free-standing, movable device that is placed next to either side of an HD machine. The H2H Module connects to the clinic’s water supply, drain, and electricity.

The H2H Module utilizes the HDF Filter, and is very similar to a typical hollow fiber dialyzer assembled with a single hollow fiber bundle made with a high-flux (or high-permeability) membrane. The fiber bundle is separated into two discrete, but serially connected, blood paths. Dialysate flows in one direction that is counter-current to blood flow in Stage 1 and co-current to blood flow in Stage 2.

In addition to the HDF Filter, the H2H Module also utilizes a Dialysate Filter during patient treatment. The Dialysate Filter is a hollow fiber, ultrafilter device that consists of two sequential (redundant) ultrafiltration stages in a single housing. During on-line HDF with the H2H Module, fresh dialysate is redirected by the H2H Module’s hydraulic (substitution) pump and passed through this dual-stage ultrafilter before being infused as substitution fluid into the extracorporeal circuit. Providing ultrapure dialysate is crucial for the success of on-line HDF treatment.

Our original HDF system conformed with current ANSI/AAMI/ISO standards and was cleared by the FDA for the treatment of patients with chronic renal failure in 2012. To date, our HDF System is the only HDF system cleared by the FDA.

Over the last four years, DaVita Healthcare Partners, the Renal Research Institute (a research division of Fresenius Medical Care), and Vanderbilt University conducted post-market evaluations of our hemodiafiltration system in their clinics. We gathered direct feedback from these evaluations to develop a better understanding of how our system best fits into the current clinical and economic ESRD treatment paradigm. The ultimate goal of the evaluations was to better understand the potential for HDF, in the U.S. clinical setting in order to (a) improve the quality of life for the patient, (b) reduce overall expenditure compared to other dialysis modalities, (c) minimize the impact on nurse work flow at the clinic, and (d) demonstrate the pharmacoeconomic benefit of the HDF technology to the U.S. healthcare system, as has been done in Europe with other HDF systems. The last evaluation was concluded at Vanderbilt in the first quarter of 2018.

#### Specialty Renal Products, Inc.

Leveraging the results of our evaluations, we recently completed development of a second-generation HDF machine prototype. We believe that the design changes will enable our HDF machine to better align with clinical work-flow practices, to be highly reliable, to simplify the training required for proficiency, and to have a dramatically lower cost of goods. We have filed for patent protection on key features of our updated design.

In July 2018, we formed a new subsidiary, Specialty Renal Products, Inc. (“SRP”), to drive the development of this second-generation HDF system. We intend to fund the HDF program primarily with funds directly raised into SRP, including a $3 million Series A Preferred Stock financing round completed in September 2018. Pending FDA clearance, we believe we can return to the market with our HDF system in the first half of 2020.

### Critical Accounting Policies

For the nine month period ended September 30, 2019, other than the adoption of Accounting Standards Codification 842, “Leases” (see Note 2, “Basis of Presentation and Liquidity,” of the Notes to our Unaudited Condensed Consolidated Interim Financial Statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference), there were no significant changes to our critical accounting policies as identified in our Annual Report on Form 10-K for the year ended December 31, 2018.

### Recent Accounting Pronouncements

We are subject to recently issued accounting standards, accounting guidance and disclosure requirements. For a description of these new accounting standards, Note 2, “Basis of Presentation and Liquidity,” of the Notes to our Unaudited Condensed Consolidated Interim Financial Statements contained in Item 1 of Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

### Results of Operations

#### Fluctuations in Operating Results

Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our annual results of operations will be impacted for the foreseeable future by several factors, including the progress and timing of expenditures related to our research and development efforts, marketing expenses related to product launches, timing of regulatory approval of our various products and market acceptance of our products. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a reliable indication of our future performance.

The following table sets forth our summarized, consolidated results of operations for the three months ended September 30, 2019 and 2018:

|  | Three Months Ended September 30, 2019 | 2018 | $ Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Total net revenues | $3,095,000 | $1,724,000 | $1,371,000 | 80% |
| Cost of goods sold | 1,276,000 | 772,000 | 504,000 | 65% |
| Gross margin | 1,819,000 | 952,000 | 867,000 | 91% |
| Gross margin % | 59% | 55% | - | 4% |
| Research and development expenses | 777,000 | 352,000 | 425,000 | 121% |
| Depreciation and amortization expense | 44,000 | 42,000 | 2,000 | 5% |
| Selling, general and administrative expenses | 1,787,000 | 1,069,000 | 718,000 | 67% |
| Change in fair value of contingent consideration | (94,000) | - | 94,000 | 100% |
| Loss from operations | (695,000) | (511,000) | 184,000 | 36% |
| Interest expense | (48,000) | (32,000) | 16,000 | 50% |
| Interest income | - | 1,000 | (1,000) | (100)% |
| Other expense, net | (1,000) | (8,000) | (7,000) | (88)% |
| Net loss | (744,000) | (550,000) | 194,000 | 35% |
| Less: Undeclared deemed dividend attributable to noncontrolling interest | (60,000) | (16,000) | 44,000 | 275% |
| Net loss attributable to Nephros, Inc. | $(804,000) | $(566,000) | $238,000 | 42% |

### Water Filtration

The following table sets forth results of operations for the Water Filtration segment for the three months ended September 30, 2019 and 2018:

|  | Three Months Ended September 30, 2019 | 2018 | $ Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Total net revenues | $3,095,000 | $1,724,000 | $1,371,000 | 80% |
| Cost of goods sold | 1,276,000 | 772,000 | 504,000 | 65% |
| Gross margin | 1,819,000 | 952,000 | 867,000 | 91% |
| Gross margin | 59% | 55% | - | 4% |
| Research and development expenses | 411,000 | 147,000 | 264,000 | 180% |
| Depreciation and amortization expense | 44,000 | 42,000 | 2,000 | 5% |
| Selling, general and administrative expenses | 1,756,000 | 970,000 | 786,000 | 81% |
| Change in fair value of contingent consideration | (94,000) | - | 94,000 | 100% |
| Loss from operations | $(298,000) | $(207,000) | $91,000 | 44% |

30

#### Net Revenues

Total net revenues for the three months ended September 30, 2019 were approximately $3,095,000 compared to approximately $1,724,000 for the three months ended September 30, 2018. The increase of approximately $1,371,000, or 80%, was driven by significant increased medical device sales, to both new and existing customer accounts, as well as our expansion into commercial markets.

#### Cost of Goods Sold

Cost of goods sold was approximately $1,276,000 for the three months ended September 30, 2019 compared to approximately $772,000 for the three months ended September 30, 2018. The increase of approximately $504,000, or 65%, occurred at a lower rate than the increase to net revenues due to a volume discount from our manufacturer of approximately $67,000. Absent this nonrecurring item, the increase in cost of goods sold would have been approximately $571,000, or 74%, which is consistent with the rate of our revenue increase.

#### Gross Margin

Gross margin was approximately 59% for the three months ended September 30, 2019 compared to approximately 55% for the three months ended September 30, 2018. The increase of approximately 4% is primarily due to a volume discount from our manufacturer recognized in the three months ended September 30, 2019.

#### Research and Development Expenses

Research and development expenses were approximately $411,000 and $147,000 for the three months ended September 30, 2019 and 2018, respectively. This increase of approximately $264,000, or 180%, reflects a net increase in expenditures on product development for our new water pathogen detection tool.

#### Depreciation and Amortization Expense

Depreciation and amortization expenses were approximately $44,000 for the three months ended September 30, 2019 compared to approximately $42,000 for the three months ended September 30, 2018. The increase of approximately $2,000, or 5%, is primarily due to amortization of intangible assets recognized in the Biocon Acquisition.

#### Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $1,756,000 for the three months ended September 30, 2019 compared to approximately $970,000 for the three months ended September 30, 2018, representing an increase of $786,000, or 81%. The increase was primarily due to increased headcount-related expenses of approximately $299,000, increased stock based compensation expense of approximately $218,000, primarily related to the vesting of options as a result of the performance condition met upon our recent Nasdaq listing, increased investor relations expenses of approximately $66,000, primarily related to our recent Nasdaq listing, increased other expenses of approximately $145,000, primarily related to rent and warehouse expenses associated with the Las Vegas facility expansion, and increased professional services marketing expenses of approximately $23,000.

#### Change in Fair Value of Contingent Consideration

Change in fair value of contingent consideration was approximately $94,000 for the three months ended September 30, 2019, due to lower than expected Biocon performance in the three months ended September 30, 2019.

#### Interest Expense

Interest expense increased approximately $16,000 primarily due to an increase in interest expense related to the secured revolving credit facility of approximately $8,000 during the three months ended September 30, 2019 and accretion expense of approximately $13,000 related to contingent consideration partially offset by a decrease in interest expense of approximately $4,000 related to the secured note payable.

#### Interest Income

There was no interest income for the three months ended September 30, 2019. Interest income of approximately $1,000 for the three months ended September 30, 2018 was a result of interest income recognized on an equipment lease. This equipment lease was terminated as a result of the Biocon Acquisition on December 31, 2018.

#### Other Expense

Other expense was approximately $1,000 and $8,000 for the three months ended September 30, 2019 and 2018, respectively, as a result of losses on foreign currency transactions.

### Renal Products

The following table sets forth results of operations for the Renal Products segment for the three months ended September 30, 2019 and 2018:

|  | Three Months Ended September 30, 2019 | 2018 | $ Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Research and development expenses | $366,000 | $205,000 | $161,000 | 79% |
| Selling, general and administrative expenses | 31,000 | 99,000 | (68,000) | (69)% |
| Loss from operations | $(397,000) | $(304,000) | $93,000 | 31% |

#### Research and Development Expenses

Research and development expenses were approximately $366,000 and $205,000 for the three months ended September 30, 2019 and 2018, respectively, an increase of approximately $161,000 due to increased investment in the development of our second-generation HDF product.

#### Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $31,000 and $99,000 for the three months ended September 30, 2019 and 2018, respectively, a decrease of approximately $68,000 primarily due to reduced administrative expenses and the absence of legal fees incurred during the three months ended September 30, 2018 as a result of the formation of SRP.

### Nine months Ended September 30, 2019 Compared to the Nine months Ended September 30, 2018

The following table sets forth our summarized, consolidated results of operations for the nine months ended September 30, 2019 and 2018:

|  | Nine months Ended September 30, 2019 | 2018 | $ Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Total net revenues | $7,173,000 | $4,075,000 | $3,098,000 | 76% |
| Cost of goods sold | 2,989,000 | 1,826,000 | 1,163,000 | 64% |
| Gross margin | 4,184,000 | 2,249,000 | 1,935,000 | 86% |
| Gross margin | 58% | 55% | - | 3% |
| Research and development expenses | 2,326,000 | 993,000 | 1,333,000 | 134% |
| Depreciation and amortization expense | 142,000 | 123,000 | 19,000 | 15% |
| Selling, general and administrative expenses | 4,693,000 | 3,420,000 | 1,273,000 | 37% |
| Change in fair value of contingent consideration | (113,000) | - | 113,000 | 100% |
| Loss from operations | (2,864,000) | (2,287,000) | 577,000 | 25% |
| Loss on extinguishment of debt | - | (199,000) | (199,000) | (100)% |
| Interest expense | (140,000) | (146,000) | (6,000) | (4)% |
| Interest income | - | 3,000 | (3,000) | (100)% |
| Other expense, net | (31,000) | (32,000) | (1,000) | (3)% |
| Net loss | (3,035,000) | (2,661,000) | 374,000 | 14% |
| Less: Undeclared deemed dividend attributable to noncontrolling interest | (180,000) | (16,000) | 164,000 | 1025% |
| Net loss attributable to Nephros, Inc. | $(3,215,000) | $(2,677,000) | $538,000 | 20% |

32

### Water Filtration

The following table sets forth results of operations for the Water Filtration segment for the nine months ended September 30, 2019 and 2018:

|  | Nine months Ended September 30, 2019 | 2018 | $ Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Total net revenues | $7,173,000 | $4,075,000 | $3,098,000 | 76% |
| Cost of goods sold | 2,989,000 | 1,826,000 | 1,163,000 | 64% |
| Gross margin | 4,184,000 | 2,249,000 | 1,935,000 | 86% |
| Gross margin | 58% | 55% | - | 3% |
| Research and development expenses | 1,190,000 | 598,000 | 592,000 | 99% |
| Depreciation and amortization expense | 142,000 | 123,000 | 19,000 | 15% |
| Selling, general and administrative expenses | 4,577,000 | 3,298,000 | 1,279,000 | 39% |
| Change in fair value of contingent consideration | (113,000) | - | 113,000 | 100% |
| Loss from operations | $(1,612,000) | $(1,770,000) | $(158,000) | (9)% |

#### Net Revenues

Total net revenues for the nine months ended September 30, 2019 were approximately $7,173,000 compared to approximately $4,075,000 for the nine months ended September 30, 2018. The increase of approximately $3,098,000, or 76%, was driven by significant increased medical device sales, to both new and existing customer accounts, as well as our expansion into commercial markets.

#### Cost of Goods Sold

Cost of goods sold was approximately $2,989,000 for the nine months ended September 30, 2019 compared to approximately $1,826,000 for the nine months ended September 30, 2018. The increase of approximately $1,163,000, or 64%, occurred at a lower rate than the increase to net revenues due to a volume discount from our manufacturer of approximately $67,000 and a decrease in expenses related to inventory adjustments and reserves for expiring items of approximately $92,000. Absent these nonrecurring items, the increase in cost of goods sold would have been approximately $1,322,000, or 76%, which is consistent with the rate of our revenue increase.

#### Gross Margin

Gross margin was approximately 58% for the nine months ended September 30, 2019 compared to approximately 55% for the nine months ended September 30, 2018. The increase of approximately 3% is primarily due to a volume discount from our manufacturer and a decrease in inventory adjustments and reserves for expiring items.

#### Research and Development Expenses

Research and development expenses were approximately $1,190,000 and $598,000 for the nine months ended September 30, 2019 and 2018, respectively. This increase of approximately $592,000, or 99%, reflects an increase in R&D headcount plus expenditures on product development for our new water pathogen detection tool.

#### Depreciation and Amortization Expense

Depreciation and amortization expenses were approximately $142,000 for the nine months ended September 30, 2019 compared to approximately $123,000 for the nine months ended September 30, 2018. The increase of approximately $19,000, or 15%, is due to amortization of intangible assets recognized in the Biocon Acquisition.

#### Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $4,577,000 for the nine months ended September 30, 2019 compared to approximately $3,298,000 for the nine months ended September 30, 2018, representing an increase of $1,279,000, or 39%. The increase was primarily due to increased headcount-related expenses of approximately $606,000, increased stock based compensation expense of approximately $63,000 , increased professional services marketing expenses of approximately $236,000, increased investor relations expenses of approximately $84,000, primarily related to our recent Nasdaq listing, and increased other expenses of approximately $216,000, primarily related to rent and warehouse expenses associated with Las Vegas and New Jersey facility expansions.

#### Change in Fair Value of Contingent Consideration

Change in fair value of contingent consideration was approximately $113,000 for the nine months ended September 30, 2019, due to lower than expected Biocon performance in the three months ended September 30, 2019.

#### Interest Expense

Interest expense decreased approximately $6,000 primarily due to interest and the related debt discount on the unsecured long-term note payable of approximately $64,000 that was paid off during the nine months ended September 30, 2018 and a decrease in interest paid to a vendor of approximately $12,000 offset partially by an increase of approximately $29,000 on interest expense on the secured note payable and the secured revolving credit facility during the nine months ended September 30, 2019 and an increase in accretion expense of approximately $41,000 related to contingent consideration during the nine months ended September 30, 2019.

#### Interest Income

There was no interest income for the nine months ended September 30, 2019. Interest income of approximately $3,000 for the nine months ended September 30, 2018 was a result of interest income recognized on an equipment lease. This equipment lease was terminated as a result of the Biocon Acquisition on December 31, 2018.

#### Other Expense

Other expense was approximately $31,000 and $32,000 for the nine months ended September 30, 2019 and 2018, respectively. Other expense for the nine months ended September 30, 2019 includes approximately $36,000 related to foreign currency transaction losses partially offset by other income of approximately $5,000. Other expense for the nine months ended September 30, 2018 is a result of losses on foreign currency transactions.

### Renal Products

The following table sets forth results of operations for the Renal Products segment for the nine months ended September 30, 2019 and 2018:

|  | Nine months Ended September 30, 2019 | 2018 | $ Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Research and development expenses | $1,136,000 | $395,000 | $741,000 | 188% |
| Selling, general and administrative expenses | 116,000 | 122,000 | (6,000) | (5)% |
| Loss from operations | $(1,252,000) | $(517,000) | $735,000 | 142% |

#### Research and Development Expenses

Research and development expenses were approximately $1,136,000 and $395,000 for the nine months ended September 30, 2019 and 2018, respectively, an increase of approximately $741,000 due to increased investment in the development of our second-generation HDF product.

#### Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $116,000 and $122,000 for the nine months ended September 30, 2019 and 2018, respectively, a decrease of approximately $6,000, primarily due to reduced administrative expenses and the absence of legal fees incurred during the three months ended September 30, 2018 as a result of the formation of SRP, partially offset by an increased investment in the development of our second-generation HDF product.

### Liquidity and Capital Resources

The following table summarizes our liquidity and capital resources as of September 30, 2019 and December 31, 2018 and is intended to supplement the more detailed discussion that follows. The amounts stated are expressed in thousands.

| Liquidity and Capital Resources | September 30, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Cash | $3,855 | $4,581 |
| Other current assets | 4,262 | 3,592 |
| Working capital | 5,001 | 5,519 |
| Stockholders’ equity | 6,722 | 6,798 |

At September 30, 2019, we had an accumulated deficit of approximately $127,188,000 and we expect to incur additional operating losses from operations until such time, if ever, that we are able to increase product sales and/or licensing revenue to achieve profitability.

Our cash flow from operations currently is not, and historically has not been, sufficient to meet our obligations and commitments. Based on cash that is available for our operations and projections of our future operations, we believe that our cash will be sufficient to fund our current operating plan through at least the next 12 months from the date of filing of this Quarterly Report on Form 10-Q. In the event that operations do not meet expectations, we will reduce discretionary expenditures such as additional headcount, new R&D projects, and other variable costs to alleviate the substantial doubt as to our ability to continue as a going concern. We may also seek to raise additional capital, however, there can be no assurance that any such actions could be affected on a timely basis or on satisfactory terms or at all, or that these actions would enable us to continue to satisfy our capital requirements.

Our future liquidity sources and requirements will depend on many factors, including:

- the market acceptance of our products and our ability to effectively and efficiently produce and market our products;
- the continued progress in, and the costs of, clinical studies and other research and development programs;
- the costs involved in filing and enforcing patent claims and the status of competitive products; and
- the cost of litigation, including potential patent litigation and any other actual or threatened litigation.

We expect to put our current capital resources to the following uses:

- the development, marketing, and sales of our water-filtration and water diagnostics products;
- the development of our second-generation HDF product; and
- working capital purposes.

At September 30, 2019, we had cash totaling approximately $3,855,000 and total assets of approximately $10,717,000, excluding other intangible assets (related to the License and Supply Agreement with Medica) of approximately $837,000.

Net cash used in operating activities was approximately $2,640,000 for the nine months ended September 30, 2019 compared to approximately $3,134,000 for the nine months ended September 30, 2018, an decrease of approximately $494,000. This decrease is due to a combination of factors, primarily lower expenditures on inventory as a result of managing inventory levels and improvements in gross margins partially offset by increased research and development expenses.

Net cash used in investing activities was approximately $151,000 for the nine months ended September 30, 2019 due to a working capital adjustment related to the Biocon Acquisition and an equipment purchase. There was no cash used in investing activities for the nine months ended September 30, 2018.

Net cash provided by financing activities of approximately $2,072,000 for the nine months ended September 30, 2019 resulted from net proceeds from the issuance of common stock of approximately $1,992,000, proceeds from the exercise of warrants of approximately $292,000, proceeds from the exercise of stock options of approximately $21,000, proceeds from equipment financing of approximately $14,000, partially offset by payments on our secured note payable of approximately $159,000, payment of contingent consideration related to the Biocon Acquisition of approximately $78,000, net payments on our secured revolving credit facility of approximately $9,000 and payments on a financing obligation of approximately $1,000.

Net cash provided by financing activities of approximately $6,269,000 for the nine months ended September 30, 2018 resulted from net proceeds from the issuance of our common stock of approximately $3,778,000, contributions from the sale of preferred stock of SRP to a noncontrolling interest of approximately $3,000,000, proceeds from the issuance of a secured note payable of approximately $1,187,000 and proceeds from the exercise of warrants of approximately $138,000, offset partially by net payments on our secured revolving credit facility of approximately $548,000, payments on our secured note payable of approximately $99,000 and payments on our unsecured long-term note payable of approximately $1,187,000.

### Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2019.

### Forward-Looking Statements

Certain statements in this Quarterly Report on Form 10-Q constitute “forward-looking statements” as defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include statements regarding the efficacy and intended use of our technologies under development, the timelines and strategy for bringing such products to market, the timeline for regulatory review and approval of our products, the availability of funding sources for continued development of such products, and other statements that are not historical facts, including statements which may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or the negative thereof or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include, but are not limited to, the risks that:

- we face significant challenges in obtaining market acceptance of our products, which could adversely affect our potential sales and revenues;
- product-related deaths or serious injuries or product malfunctions could trigger recalls, class action lawsuits and other events that could cause us to incur expenses and may also limit our ability to generate revenues from such products;
- we face potential liability associated with the production, marketing and sale of our products, and the expense of defending against claims of product liability could materially deplete our assets and generate negative publicity, which could impair our reputation;
- to the extent our products or marketing materials are found to violate any provisions of the U.S. Food, Drug and Cosmetic Act or any other statutes or regulations, we could be subject to enforcement actions by the FDA or other governmental agencies;
- we may not be able to obtain funding if and when needed or on terms favorable to us in order to continue operations;
- we may not have sufficient capital to successfully implement our business plan;
- we may not be able to effectively market our products;
- we may not be able to sell our water filtration products or chronic renal failure therapy products at competitive prices or profitably;
- we may encounter problems with our suppliers, manufacturers and distributors;
- we may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures;
- we may not obtain appropriate or necessary regulatory approvals to achieve our business plan;
- products that appeared promising to us in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre-clinical or clinical trials;
- we may not be able to secure or enforce adequate legal protection, including patent protection, for our products; and
- we may not be able to achieve sales growth in key geographic markets.

More detailed information about us and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Quarterly Report on Form 10-Q, is set forth in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2018. We urge investors and security holders to read those documents free of charge at the SEC’s web site at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.

## Controls and procedures

As filed, 1,682 characters.

### Evaluation of Disclosure Controls and Procedures

We maintain a system of disclosure controls and procedures, as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which is designed to provide reasonable assurance that information required to be disclosed in our reports filed pursuant to the Exchange Act is accumulated and communicated to management in a timely manner. Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud have been or will be detected.

At the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, regarding the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Nov 6, 2019.
Source: SEC EDGAR, the filing index for accession 0001493152-19-016513. Last ingested by Listed: Nov 13, 2026, 16:20 ET. No prices; not investment advice.
